Disclosures for "Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial ")
-
Ms. Kayne has nothing to disclose.
-
Dr. Poiset has nothing to disclose.
-
Dr. Ali has nothing to disclose.
-
Dr. Miller has nothing to disclose.
-
Dr. Niazi has nothing to disclose.
-
Dr. Cappelli has nothing to disclose.
-
The institution of Dr. Alnahhas has received research support from Novocure.
-
Dr. Shi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure. Dr. Shi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for zai lab. Dr. Shi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for varian. Dr. Shi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novocure.